Cargando…

Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI)

Acyl coenzyme A binding protein (ACBP), also known as diazepam binding inhibitor (DBI) is a multifunctional protein with an intracellular action (as ACBP), as well as with an extracellular role (as DBI). The plasma levels of soluble ACBP/DBI are elevated in human obesity and reduced in anorexia nerv...

Descripción completa

Detalles Bibliográficos
Autores principales: Joseph, Adrien, Moriceau, Stéphanie, Sica, Valentina, Anagnostopoulos, Gerasimos, Pol, Jonathan, Martins, Isabelle, Lafarge, Antoine, Maiuri, Maria Chiara, Leboyer, Marion, Loftus, Josephine, Bellivier, Frank, Belzeaux, Raoul, Berna, Fabrice, Etain, Bruno, Capdevielle, Delphine, Courtet, Philippe, Dubertret, Caroline, Dubreucq, Julien, Thierry, D’. Amato, Fond, Guillaume, Gard, Sebastien, Llorca, Pierre-Michel, Mallet, Jasmina, Misdrahi, David, Olié, Emilie, Passerieux, Christine, Polosan, Mircea, Roux, Paul, Samalin, Ludovic, Schürhoff, Franck, Schwan, Raymond, Magnan, Christophe, Oury, Franck, Bravo-San Pedro, José M., Kroemer, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338362/
https://www.ncbi.nlm.nih.gov/pubmed/32632162
http://dx.doi.org/10.1038/s41419-020-2716-5
_version_ 1783554657181761536
author Joseph, Adrien
Moriceau, Stéphanie
Sica, Valentina
Anagnostopoulos, Gerasimos
Pol, Jonathan
Martins, Isabelle
Lafarge, Antoine
Maiuri, Maria Chiara
Leboyer, Marion
Loftus, Josephine
Bellivier, Frank
Belzeaux, Raoul
Berna, Fabrice
Etain, Bruno
Capdevielle, Delphine
Courtet, Philippe
Dubertret, Caroline
Dubreucq, Julien
Thierry, D’. Amato
Fond, Guillaume
Gard, Sebastien
Llorca, Pierre-Michel
Mallet, Jasmina
Misdrahi, David
Olié, Emilie
Passerieux, Christine
Polosan, Mircea
Roux, Paul
Samalin, Ludovic
Schürhoff, Franck
Schwan, Raymond
Magnan, Christophe
Oury, Franck
Bravo-San Pedro, José M.
Kroemer, Guido
author_facet Joseph, Adrien
Moriceau, Stéphanie
Sica, Valentina
Anagnostopoulos, Gerasimos
Pol, Jonathan
Martins, Isabelle
Lafarge, Antoine
Maiuri, Maria Chiara
Leboyer, Marion
Loftus, Josephine
Bellivier, Frank
Belzeaux, Raoul
Berna, Fabrice
Etain, Bruno
Capdevielle, Delphine
Courtet, Philippe
Dubertret, Caroline
Dubreucq, Julien
Thierry, D’. Amato
Fond, Guillaume
Gard, Sebastien
Llorca, Pierre-Michel
Mallet, Jasmina
Misdrahi, David
Olié, Emilie
Passerieux, Christine
Polosan, Mircea
Roux, Paul
Samalin, Ludovic
Schürhoff, Franck
Schwan, Raymond
Magnan, Christophe
Oury, Franck
Bravo-San Pedro, José M.
Kroemer, Guido
author_sort Joseph, Adrien
collection PubMed
description Acyl coenzyme A binding protein (ACBP), also known as diazepam binding inhibitor (DBI) is a multifunctional protein with an intracellular action (as ACBP), as well as with an extracellular role (as DBI). The plasma levels of soluble ACBP/DBI are elevated in human obesity and reduced in anorexia nervosa. Accumulating evidence indicates that genetic or antibody-mediated neutralization of ACBP/DBI has anorexigenic effects, thus inhibiting food intake and inducing lipo-catabolic reactions in mice. A number of anorexiants have been withdrawn from clinical development because of their side effects including an increase in depression and suicide. For this reason, we investigated the psychiatric impact of ACBP/DBI in mouse models and patient cohorts. Intravenously (i.v.) injected ACBP/DBI protein conserved its orexigenic function when the protein was mutated to abolish acyl coenzyme A binding, but lost its appetite-stimulatory effect in mice bearing a mutation in the γ2 subunit of the γ-aminobutyric acid (GABA) A receptor (GABA(A)R). ACBP/DBI neutralization by intraperitoneal (i.p.) injection of a specific mAb blunted excessive food intake in starved and leptin-deficient mice, but not in ghrelin-treated animals. Neither i.v. nor i.p. injected anti-ACBP/DBI antibody affected the behavior of mice in the dark–light box and open-field test. In contrast, ACBP/DBI increased immobility in the forced swim test, while anti-ACBP/DBI antibody counteracted this sign of depression. In patients diagnosed with therapy-resistant bipolar disorder or schizophrenia, ACBP/DBI similarly correlated with body mass index (BMI), not with the psychiatric diagnosis. Patients with high levels of ACBP/DBI were at risk of dyslipidemia and this effect was independent from BMI, as indicated by multivariate analysis. In summary, it appears that ACBP/DBI neutralization has no negative impact on mood and that human depression is not associated with alterations in ACBP/DBI concentrations.
format Online
Article
Text
id pubmed-7338362
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-73383622020-07-09 Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI) Joseph, Adrien Moriceau, Stéphanie Sica, Valentina Anagnostopoulos, Gerasimos Pol, Jonathan Martins, Isabelle Lafarge, Antoine Maiuri, Maria Chiara Leboyer, Marion Loftus, Josephine Bellivier, Frank Belzeaux, Raoul Berna, Fabrice Etain, Bruno Capdevielle, Delphine Courtet, Philippe Dubertret, Caroline Dubreucq, Julien Thierry, D’. Amato Fond, Guillaume Gard, Sebastien Llorca, Pierre-Michel Mallet, Jasmina Misdrahi, David Olié, Emilie Passerieux, Christine Polosan, Mircea Roux, Paul Samalin, Ludovic Schürhoff, Franck Schwan, Raymond Magnan, Christophe Oury, Franck Bravo-San Pedro, José M. Kroemer, Guido Cell Death Dis Article Acyl coenzyme A binding protein (ACBP), also known as diazepam binding inhibitor (DBI) is a multifunctional protein with an intracellular action (as ACBP), as well as with an extracellular role (as DBI). The plasma levels of soluble ACBP/DBI are elevated in human obesity and reduced in anorexia nervosa. Accumulating evidence indicates that genetic or antibody-mediated neutralization of ACBP/DBI has anorexigenic effects, thus inhibiting food intake and inducing lipo-catabolic reactions in mice. A number of anorexiants have been withdrawn from clinical development because of their side effects including an increase in depression and suicide. For this reason, we investigated the psychiatric impact of ACBP/DBI in mouse models and patient cohorts. Intravenously (i.v.) injected ACBP/DBI protein conserved its orexigenic function when the protein was mutated to abolish acyl coenzyme A binding, but lost its appetite-stimulatory effect in mice bearing a mutation in the γ2 subunit of the γ-aminobutyric acid (GABA) A receptor (GABA(A)R). ACBP/DBI neutralization by intraperitoneal (i.p.) injection of a specific mAb blunted excessive food intake in starved and leptin-deficient mice, but not in ghrelin-treated animals. Neither i.v. nor i.p. injected anti-ACBP/DBI antibody affected the behavior of mice in the dark–light box and open-field test. In contrast, ACBP/DBI increased immobility in the forced swim test, while anti-ACBP/DBI antibody counteracted this sign of depression. In patients diagnosed with therapy-resistant bipolar disorder or schizophrenia, ACBP/DBI similarly correlated with body mass index (BMI), not with the psychiatric diagnosis. Patients with high levels of ACBP/DBI were at risk of dyslipidemia and this effect was independent from BMI, as indicated by multivariate analysis. In summary, it appears that ACBP/DBI neutralization has no negative impact on mood and that human depression is not associated with alterations in ACBP/DBI concentrations. Nature Publishing Group UK 2020-07-06 /pmc/articles/PMC7338362/ /pubmed/32632162 http://dx.doi.org/10.1038/s41419-020-2716-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Joseph, Adrien
Moriceau, Stéphanie
Sica, Valentina
Anagnostopoulos, Gerasimos
Pol, Jonathan
Martins, Isabelle
Lafarge, Antoine
Maiuri, Maria Chiara
Leboyer, Marion
Loftus, Josephine
Bellivier, Frank
Belzeaux, Raoul
Berna, Fabrice
Etain, Bruno
Capdevielle, Delphine
Courtet, Philippe
Dubertret, Caroline
Dubreucq, Julien
Thierry, D’. Amato
Fond, Guillaume
Gard, Sebastien
Llorca, Pierre-Michel
Mallet, Jasmina
Misdrahi, David
Olié, Emilie
Passerieux, Christine
Polosan, Mircea
Roux, Paul
Samalin, Ludovic
Schürhoff, Franck
Schwan, Raymond
Magnan, Christophe
Oury, Franck
Bravo-San Pedro, José M.
Kroemer, Guido
Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI)
title Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI)
title_full Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI)
title_fullStr Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI)
title_full_unstemmed Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI)
title_short Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI)
title_sort metabolic and psychiatric effects of acyl coenzyme a binding protein (acbp)/diazepam binding inhibitor (dbi)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338362/
https://www.ncbi.nlm.nih.gov/pubmed/32632162
http://dx.doi.org/10.1038/s41419-020-2716-5
work_keys_str_mv AT josephadrien metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT moriceaustephanie metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT sicavalentina metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT anagnostopoulosgerasimos metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT poljonathan metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT martinsisabelle metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT lafargeantoine metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT maiurimariachiara metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT leboyermarion metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT loftusjosephine metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT bellivierfrank metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT belzeauxraoul metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT bernafabrice metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT etainbruno metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT capdevielledelphine metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT courtetphilippe metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT dubertretcaroline metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT dubreucqjulien metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT thierrydamato metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT fondguillaume metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT gardsebastien metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT llorcapierremichel metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT malletjasmina metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT misdrahidavid metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT olieemilie metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT passerieuxchristine metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT polosanmircea metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT rouxpaul metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT samalinludovic metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT schurhofffranck metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT schwanraymond metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT magnanchristophe metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT ouryfranck metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT bravosanpedrojosem metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi
AT kroemerguido metabolicandpsychiatriceffectsofacylcoenzymeabindingproteinacbpdiazepambindinginhibitordbi